Understanding Brain Reward Responses in Individuals With Major Depressive Disorder
NCT ID: NCT00183755
Last Updated: 2014-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
87 participants
OBSERVATIONAL
2005-04-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroimaging Studies of Reward Processing in Depression
NCT03026036
Brain Imaging of Psychotherapy for Depression
NCT00609453
Brain Regulation of Emotions in People With Depression and Anhedonia
NCT00059579
Reward-Related Processes and Brain Function
NCT00029588
Brain Mechanisms of Human Motivation
NCT01976975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Event-related potential (ERP), which measures electrical activity in the brain, and functional magnetic resonance imaging (fMRI), which uses scanned images to illustrate changes in brain activity, are two techniques that can identify abnormal areas of brain processing. The purpose of this study is to use ERP and fMRI to compare brain activity that is related to reward processing in individuals with MDD versus individuals without MDD.
This study will consist of 3 study visits; visits will be scheduled as close together as possible. At the first study visit, potential participants will be assessed with the SCID (Structured Clinical Interview for DSM-IV), which will identify individuals with the diagnostic criteria for MDD. A control group of non-depressed individuals will also be enrolled in the study. During the second and third study visits, participants will take part in a monetary reinforcement reward task followed by a signal detection reward task. Brain activity of all participants will be monitored during both tasks. During the second study visit, ERP will be used; during the third study visit, fMRI will be used. Demographic information will also be collected, and participants will complete several standardized questionnaires to assess mood. Some participants will be asked to return after eight weeks to complete the fMRI and EEG sessions again. Those who do complete all five sessions will be awarded a bonus.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Control participants
No interventions assigned to this group
2
Participants with MDD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agrees to use an effective form of contraception throughout the study
* Meets DSM-IV diagnosis criteria for major depressive disorder
* Score of at least 16 on the 21-item HAM-D scale
Exclusion Criteria
* Claustrophobic
* Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head injury, loss of consciousness, seizures)
* Pregnant
* Has been treated with electroconvulsive therapy within 6 months of study entry
* Has taken any benzodiazepine medications for at least 2 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
* Has taken any dopaminergic medications (including methylphenidate) or neuroleptics for at least 6 months prior to study entry and discontinued use of the medication for reasons other than participating in the study
* Has taken any fluoxetine medications for at least 6 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
* Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
* Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
* Current or past history of MDD with psychotic features
* Meets DSM-IV diagnosis criteria for organic mental disorder; substance use disorder (within 1 year of study entry); lifetime substance dependence; schizophrenia; delusional disorder; bipolar disorder; post-traumatic stress disorder; eating disorder; acute bereavement; severe borderline or antisocial personality disorder; or any psychotic disorder not otherwise specified
* Current primary diagnosis of panic disorder, social phobia, generalized anxiety disorder, obsessive-compulsive disorder, or somatoform disorder
* Diagnosed with any medical or neurological illness
* Diagnosed with any current or past psychiatric illness, as assessed by the SCID-I, including substance abuse or dependence (e.g., alcohol)
* Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
* Has taken any psychotropic medications within 2 weeks of study entry
* Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
* Fails to meet safety standards for fMRI
* Current back problems
* Has strongly corrected vision, but does not wear contact lenses
* Weighs more than 250 pounds or exceeds the limit of height-to-weight ratio for a comfortable fit in the scanner
* Pregnant
* Current alcohol or substance abuse
* At risk for suicide or homicide
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Mclean Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diego A. Pizzagalli
Associate Professor, Harvard Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diego A. Pizzagalli, PhD
Role: PRINCIPAL_INVESTIGATOR
Harvard University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
Affective Neuroscience Laboratory, Department of Psychology, Harvard University
Cambridge, Massachusetts, United States
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009 Jun;166(6):702-10. doi: 10.1176/appi.ajp.2008.08081201. Epub 2009 May 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.